TRICARE Pharmacy Program Medical Necessity Form for ACE Inhibitors and ACE Inhibitor/HCTZ Combination Products

This form applies to the TRICARE Mail Order Pharmacy (TMOP) and the TRICARE Retail Pharmacy Program (TRRx) and may be found on the TRICARE Pharmacy website at www.tricare.osd.mil/pharmacy/medical-nonformulary.cfm. The medical necessity criteria outlined on this form also apply at Military Treatment Facilities (MTFs). The form must be completed and signed by the prescriber.

- Benazepril, captopril, enalapril, fosinopril, lisinopril, their combinations with hydrochlorothiazide (HCTZ), and trandolapril (Mavik) are the formulary angiotensin converting enzyme (ACE) inhibitors and ACE inhibitor/HCTZ combinations on the DoD Uniform Formulary. Accupril (quinapril), Accuretic (quinapril/HCTZ), Aceon (perindopril), Altace (ramipril), Univasc (moexipril), and Uniretic (moexipril/HCTZ) are non-formulary, but available to most beneficiaries at a \$22 cost share.
- You do NOT need to complete this form in order for non-active duty beneficiaries (spouses, dependents, and retirees) to obtain nonformulary medications at the \$22 non-formulary cost share. The purpose of this form is to provide information that will be used to determine if the use of a non-formulary medication instead of a formulary medication is medically necessary. If a non-formulary medication is determined to be medically necessary, non-active duty beneficiaries may obtain it at the \$9 formulary cost share.
- Active duty service members may not fill prescriptions for a non-formulary medication unless it is determined to be medically necessary. There is no cost share for active duty service members at any DoD pharmacy point of service

MAIL ORDER	If the prescription is to be filled through the TRICARE Mail Order Pharmacy, check here • The completed form and the prescription may be faxed to 1-877-283-8075 or 1-602-586-3915 OR • The patient may attach the completed form to the prescription and mail it to: Express Scripts, P.O. Box 52150, Phoenix, AZ 85072-9954	RETAIL	If the prescription is to be filled at a retail network pharmacy, check here • The provider may call: 1-866-684-4488 OR • The completed form may be faxed to 1-866-684-4477	MTF	Non-formulary medications are available at MTFs only if both of the following are true: The prescription is written by a military provider or, at the discretion of the MTF, a civilian provider to whom the patient was referred by the MTF. The non-formulary medication is determined to be medically necessary. Please contact your local MTF for more information. There are no cost shares at MTFs.				
There is no expiration date for approved medical necessity determinations.									
St	Please complete patient and Patient Name: Address:	ph	ysician information (Please Prin Physician Name: Address:						
	Sponsor ID #		Phone #: Secure Fax #:						
	Please explain why the patPlease indicate which of the reas		•		ne formulary alternatives: ormulary alternatives listed in the table.				

You MUST circle a reason AND supply a written clinical explanation specific for EACH formulary alternative.

Formulary Alternative	Reason	Clinical Explanation
Benazepril, benazepril/HCTZ (Lotensin, Lotensin HCT)	1 2 3 4 5	
Enalapril, enalapril/HCTZ (Vasotec, Vasoretic)	1 2 3 4 5	
Fosinopril, fosinopril/HCTZ (Monopril, Monopril-HCT)	1 2 3 4 5	
Lisinopril; lisinopril/HCTZ (Prinivil, Zestril; Prinzide, Zestoretic)	1 2 3 4 5	
Trandolapril (Mavik)	1 2 3 4 5	

The criteria do not include captopril as a formulary alternative due to its short half-life and three- to four-time daily dosing regimen. Patients are not required to have tried captopril.

Acceptable clinical reasons for not using a formulary alternative are:

- 1. The formulary alternative is contraindicated (e.g., due to a hypersensitivity reaction).
- 2. The patient has experienced significant adverse effects with the formulary alternative that are not expected to occur with the non-formulary ACE inhibitor.
- 3. Use of the formulary alternative resulted in therapeutic failure.
- 4. The patient is stabilized on a non-formulary ACE inhibitor, is clinically fragile (multiple comorbidities), and changing to a formulary alternative would incur an unacceptable risk to the patient (e.g., destabilization, abrupt worsening of symptoms).
- 5. Altace is more appropriate than the formulary alternative because the patient has a history of stroke, MI, peripheral vascular disease, or diabetes AND is at high risk for future cardiovascular events due to hypertension, documented

	microalbuminuria, total cholesterol > 200 mg/dL, low HDL space above). This subset of patients is not required to try	<35 mg/dL, or smoking (provide a clin	•			
Step 3	I certify the above is correct and accurate to the best of my knowledge. Please sign and date:					
	Prescriber Signature	Date				
			Latest revision: October 2005			